Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

Simple Summary The coexistence of cancer with other chronic conditions has substantial implications for treatment decisions and outcomes for both neoplasms and chronic disease. Reports have demonstrated the impact of comorbidities on survival in different hematologic disorders. Myelofibrosis (MF) guidelines do not consider the complex interrelations between MF and comorbidity. Several works have shown how MF patients have a wide variety and high burden of comorbidities and demonstrated that the comorbidity burden was significantly associated with an unfavorable impact on survival. These previous studies about comorbidity on MF are retrospective and consider the cumulative rather than individual comorbidity burden. The influence of individual comorbidities on outcome in MF patients has not been studied. We sought to identify the comorbidities in MF patients at diagnosis and to assess the influence of those different comorbidities on survival. Considering them individually may contribute to the personalization of MF management and optimizing outcomes. Abstract The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p < 0.001), smoking (HR = 5.08, p < 0.001), dyslipidemia (HR = 4.65, p < 0.001) and hepatitis C virus (HCV) (HR = 4.26, p = 0.015) were most adversely associated with OS. Diabetes (HR = 3.01, p < 0.001), pulmonary disease (HR = 3.13, p < 0.001) and renal dysfunction (HR = 1.82, p = 0.037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2.69, p = 0.001), smoking (HR = 3.34, p < 0.001), renal dysfunction (HR = 2.08, p = 0.043) and HCV (HR = 11.49, p = 0.001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF.

[1]  Gang Li,et al.  Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells. , 2020, Microvascular research.

[2]  H. Hasselbalch,et al.  Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms – Impact Of Comorbidity , 2019, Clinical epidemiology.

[3]  R. Foà,et al.  Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib , 2018, Annals of Hematology.

[4]  P. Campbell,et al.  Classification and Personalized Prognosis in Myeloproliferative Neoplasms , 2018, The New England journal of medicine.

[5]  Si‐Hyuck Kang,et al.  Blood Pressure Control and Cardiovascular Outcomes: Real-world Implications of the 2017 ACC/AHA Hypertension Guideline , 2018, Scientific Reports.

[6]  Jennifer Y. Liu,et al.  The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study) , 2018, Diabetes Care.

[7]  S. James,et al.  Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib , 2018, Cancer.

[8]  P. Guglielmelli,et al.  MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Guglielmelli,et al.  GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis , 2018, Leukemia.

[10]  H. Haybar,et al.  Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms. , 2018, Cardiovascular & hematological disorders drug targets.

[11]  Á. Payer,et al.  Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis , 2018, Leukemia.

[12]  M. Cazzola,et al.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Harrison,et al.  Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. , 2017, Hematology. American Society of Hematology. Education Program.

[14]  M. Landray,et al.  Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation , 2017, Kidney international.

[15]  T. Panzarella,et al.  Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm‐Associated Myelofibrosis: A Retrospective Cohort Study , 2017, Clinical lymphoma, myeloma & leukemia.

[16]  T. Gray,et al.  Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia , 2017, Current Geriatrics Reports.

[17]  M. Cazzola,et al.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. , 2017, Blood.

[18]  A. Tefferi,et al.  Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management , 2016 .

[19]  S. Devesa,et al.  Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12 , 2016, British journal of haematology.

[20]  D. Sarfati,et al.  The impact of comorbidity on cancer and its treatment , 2016, CA: a cancer journal for clinicians.

[21]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[22]  A. Tefferi,et al.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.

[23]  M. Griesshammer,et al.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group , 2015, Leukemia.

[24]  Martin C. Müller,et al.  Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. , 2015, Blood.

[25]  M. Cazzola,et al.  Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. , 2015, Blood.

[26]  H. Hasselbalch,et al.  The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms , 2015, Clinical case reports.

[27]  M. Cazzola,et al.  Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project , 2014 .

[28]  S. Verstovsek,et al.  Comorbidities predict worse prognosis in patients with primary myelofibrosis , 2014, Cancer.

[29]  G. Limongelli,et al.  Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target , 2014, Current Atherosclerosis Reports.

[30]  U. Iqbal,et al.  Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union , 2014, European journal of haematology.

[31]  H. Hasselbalch.  Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms , 2014, Expert review of hematology.

[32]  N. Milic,et al.  Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis , 2014, Medical Oncology.

[33]  F. Passamonti,et al.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.

[34]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[35]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[36]  M. Griesshammer,et al.  Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Steyerberg,et al.  Comparison of Scoring Methods for ACE-27: Simpler Is Better. , 2012, Journal of geriatric oncology.

[38]  M. Suarez‐Almazor,et al.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[41]  M. Sorror,et al.  Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[43]  P. Campbell,et al.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.

[44]  A. Tefferi.  Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Lipton,et al.  Impact of comorbidities constituting the HCT-CI score on the outcome of patients undergoing allogeneic HCT for AML. , 2017 .